TLR2 and Alzheimer disease: Previously, we found that the TLR2 agonist Pam3CSK4 induced the expression of FcεRI on circulating monocytes in patients with moderate or severe AD through the p38 MAPK signaling pathway (22), suggesting that the interaction between FcεRI and TLR2 also occurs in AD that needs further verification.